secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001193125-26-142114
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio SVP Finance to depart April 30; CFO adds principal accounting officer role
--------------------------------------------------------------------------------

- Cindy Driscoll, SVP Finance and principal accounting officer, to separate from Climb Bio effective April 30, 2026, by mutual agreement.
- CFO Susan Altschuller will also serve as principal accounting officer starting on the Separation Date.
- Altschuller has been CFO since Oct 2025; prior CFO roles at Dragonfly Therapeutics, Cerevel Therapeutics, and ImmunoGen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526142114/0001193125-26-142114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526142114/d59877d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-142114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer